Kyeong-ryoon T. Lee
Daejeon, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 59 publications
Structure-Guided Identification of Phytochemical OCT2 Inhibitors and Their Functional Relevance to Cisplatin-Induced Cytotoxicity.
Journal: Pharmaceutics
Published: March 19, 2026
Gut microbiome-related tryptophan metabolites modulate drug transporters, with prominent effects on OAT1 and OAT3.
Journal: Toxicology and applied pharmacology
Published: March 12, 2026
Development of Novel Small-Molecule Targeting SCN1A-Associated Severe Myoclonic Epilepsy of Infancy.
Development of Novel Small-Molecule Targeting SCN1A-Associated Severe Myoclonic Epilepsy of Infancy.
Journal: Journal of medicinal chemistry
Published: January 23, 2026
Pharmacokinetic Landscape and Interaction Potential of SGLT2 Inhibitors: Bridging In Vitro Findings and Clinical Implications.
Journal: Pharmaceutics
Published: October 17, 2025
Development and validation of an LC-MS/MS method for Tirzepatide, a dual GIP/GLP-1 receptor agonist, in rat plasma for application to a pharmacokinetic study.
Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
Published: September 10, 2025
Inhibition of breast cancer resistance protein by flavonols: in vitro, in vivo, and in silico implications of the interactions.
Journal: Scientific reports
Published: May 30, 2025
Integrating analytical quality by design into bioanalytical method development: an HPLC-FLD method for quantification of alectinib in biological matrix.
Journal: BMC chemistry
Published: April 24, 2025
Identification of flavonol derivatives inhibiting MDR1: a strategy to overcome multidrug resistance in cancer.
Journal: Natural product research
Published: November 05, 2024
Drug Interaction-Informed Approaches to Inflammatory Bowel Disease Management.
Journal: Pharmaceutics
Published: September 09, 2024
Interactions of bosutinib with drug transporters: In vitro and In vivo inhibition of organic cation transporter 2, multidrug and toxin extrusion protein 1, and breast cancer resistance protein by bosutinib.
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: May 31, 2024
A Phase I, Open-Label, Sequential, Single-Dose Clinical Trial to Evaluate the Pharmacokinetic, Pharmacodynamic, and Safety of IVL3001, a Finasteride-Based Novel Long-Acting Injection for Androgenetic Alopecia.
Journal: Advances in therapy
Published: March 25, 2024
Last Updated: 09/26/2026